Multimodality management of squamous cell carcinoma of thoracic esophagus.
- Author:
Zhe-xin WANG
1
;
Teng MAO
;
Xu-feng GUO
;
Wen-tao FANG
Author Information
1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai 200030, China. vwtfang@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Squamous Cell;
drug therapy;
radiotherapy;
surgery;
Chemotherapy, Adjuvant;
Combined Modality Therapy;
Esophageal Neoplasms;
drug therapy;
radiotherapy;
surgery;
Humans;
Prospective Studies;
Radiotherapy, Adjuvant
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(9):815-818
- CountryChina
- Language:Chinese
-
Abstract:
Most patients with esophageal cancer have advanced disease at presentation. The efficacy of surgical resection alone is often unsatisfactory in patients with stage III or more advanced cancer according to the seventh edition of UICC staging system for esophageal cancer. The systematic multidisciplinary treatment is important. Mounting evidence indicates that preoperative concurrent chemoradiotherapy is the most effective induction therapy to down-stage tumor and increase radical resection rate. For the esophageal squamous cell carcinoma patients with multi-stations and multi-fields lymph node metastasis, preoperative induction chemotherapy would be a viable option. For locally advanced cancers which have been surgically resected, postoperative adjuvant radiotherapy maybe helpful to improve local control for the insufficient surgical dissection. The role of adjuvant chemotherapy also needs further studies. Thoracic esophageal squamous cell carcinoma and lower esophageal adenocarcinoma which is common in western countries are different. We need more prospective clinical studies to establish our treatment modalities for esophageal cancer.
